Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma

REFERENCES

• Veronesi U., Boyle P., Goldhirsch A., Orecchia R., Viale G. Breast cancer. Lancet 2005; 365: 1727–1741
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717
   PubMed Web of Science ®Google Scholar
• Estevez L. G., Gradishar W. J. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004; 10: 3249–3261
   PubMed Web of Science ®Google Scholar
• Kaufmann M., Hortobagyi G. N., Goldhirsch A., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940–1949
   PubMed Web of Science ®Google Scholar
• Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707–1715
   PubMed Web of Science ®Google Scholar
• Dieras V., Fumoleau P., Romieu G., et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958–4965
   PubMed Web of Science ®Google Scholar
• Faneyte I. F., Schrama J. G., Peterse J. L., Remijnse P. L., Rodenhuis S., van de Vijver M. J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88: 406–412
   PubMed Web of Science ®Google Scholar
• Kandioler-Eckersberger D., Ludwig C., Rudas M., et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50–56
   PubMed Web of Science ®Google Scholar
• Bouchalova K., Trojanec R., Kolár Z., et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 2006; 53: 393–401
   PubMed Web of Science ®Google Scholar
• Murta E. F. C., de Andrade J. M., Falcao R. P., Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 2000; 86: 403–407
   PubMed Web of Science ®Google Scholar
• Pusztai L., Mendoza T. R., Reuben J. M., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004; 25: 94–102
   PubMed Web of Science ®Google Scholar
• Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P., Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002; 87: 21–27
   PubMed Web of Science ®Google Scholar
• Melichar B., Touskova M., Hornychova H., et al. Systemic immune activation and peripheral blood lymphocytes during primary chemotherapy with the combination of doxorubicin and paclitaxel. Pteridines 2007; 18: 25–34
   Web of Science ®Google Scholar
• Tavasoli F. A., Deviler P. Pathology and genetics of tumours of the breast and female genital organs. World Health Organisation Classification of Tumours, P. Kleinhues, L. H. Sogin. IARC Press, Lyon 2003
   Google Scholar
• Chevallier B., Roche H., Olivier J. P., Chollet P., Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in high histologic response rate. Am. J. Clin. Oncol 1993; 16: 223–228
   PubMed Web of Science ®Google Scholar
• Remmele W., Stegner H. E. Vorschlag zu einheitlichen Definition eines immunoreactives Score (IRS) fur immunhistochemischen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 1987; 8: 138–140
   PubMed Web of Science ®Google Scholar
• Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• Tomšová M., Melichar B., Sedláková I., Šteiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gyn Oncol 2008; 108: 415–420
   PubMed Web of Science ®Google Scholar
• Demaria S., Volm M. D., Shapiro R. L., et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001; 7: 3025–3030
   PubMed Web of Science ®Google Scholar
• Lucin K., Iternicka Z., Jonjic N. Prognostic significance of T-cell infiltrates, expression of beta2. microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1994; 190: 1134–1140
   PubMed Web of Science ®Google Scholar
• Wang B. L., Springer G. F., Kaufmamn M. W. Concurrent immunohistochemical staining of tumor-infiltrating lymphocytes and carcinoma-associated T (Thomsen-Friedenreich) Tn antigens in human breast carcinoma. J Histochem Cytochem 1996; 44: 187–191
   PubMed Web of Science ®Google Scholar
• Georgiannos S. N., Renaut A., Goode A. W., Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their associatin with prognostic indicators. Surgery 2003; 134: 827–834
   PubMed Web of Science ®Google Scholar
• Leong P. P., Mohammad R., Ibrahim N., et al. Phenotyping of lymphocytes exxpressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006; 102: 229–236
   PubMed Web of Science ®Google Scholar
• Wong P. Y., Staren E. D., Tereshkova N., Braun D. P. Functional analysis of tumor-infiltrating lekocytes in breast cancer patients. J Surg Res 1998; 76: 95–103
   PubMed Web of Science ®Google Scholar
• Menard S., Tomasic G., Casalini P., et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997; 3: 817–819
   PubMed Web of Science ®Google Scholar
• Iwamoto M., Shinohara H., Miyamoto A., et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104: 92–97
   PubMed Web of Science ®Google Scholar
• Ueno T., Toi M., Saji H., et al. Significance of macrophage chemico attractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282–3289
   PubMed Web of Science ®Google Scholar
• Lewis J. S., Landers R. J., Underwood C. E., Harris A. L., Lewis C. E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000; 192: 150–158
   PubMed Web of Science ®Google Scholar
• Pupa S. M., Bufalino R., Invernizzi A. M., et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 1996; 14: 85–94
   PubMed Web of Science ®Google Scholar
• O'Sullivan C., Lewis C. E. Tumor-associated leucocytes: friends or foes in breast carcinoma. J Pathol 1994; 172: 229–235
   PubMed Web of Science ®Google Scholar
• Parshad R., Kapoor S., Gupta S. D., Kumar A., Chattopadhyaya T. K. Does famotidine enhance tumor-infiltrating lymphocytes in breast cancer?. Acta Oncol 2002; 2002: 362–365
   Google Scholar
• Chollet P., Amat S., Cure H., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86: 1041–1046
   PubMed Web of Science ®Google Scholar
• Bear H. D., Anderson S., Smith R. E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006; 24: 2019–2027
   PubMed Web of Science ®Google Scholar
• Machiavelli M. R., Romero A. O., Perez J. E., et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998; 4: 125–131
   PubMed Web of Science ®Google Scholar
• Thomas E., Holmes F. A., Smith T. L., et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective, randomized trial. J Clin Oncol 2004; 22: 2294–2302
   PubMed Web of Science ®Google Scholar
• Arnould L., Gelly M., Penault-Llorca F., et al. Trastuzumab-based treatment of HER2-positive breast cancer an antibody-dependent cellular cyotoxicity mechanism?. Br J Cancer 2006; 94: 259–267
   PubMed Web of Science ®Google Scholar
• Chang J. C., Wooten E. C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362–369
   PubMed Web of Science ®Google Scholar
• van de Vijver M. J., He Y. F., van't Veer L. J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009
   PubMed Web of Science ®Google Scholar
• Steinman R. M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271–296
   PubMed Web of Science ®Google Scholar
• Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357: 539–545
   PubMed Web of Science ®Google Scholar
• Elgert K. D., Alleva D. G., Mullins D. W. Tumor-induced immune dysfunction: the macrophage connection. J Leukocyte Biol 1998; 64: 275–290
   PubMed Web of Science ®Google Scholar
• Alleva D. G., Burger C. J., Elgert K. D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E. J Immunol 1994; 153: 1674–1686
   Google Scholar
• Uyttenhove C., Pilotte L., Theate I., et al. Evidence for a tumor immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269–1274
   PubMed Web of Science ®Google Scholar
• Dales J. P., Garcia S., Bonnier P., et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Am J Clin Pathol 2003; 119: 374–380
   PubMed Web of Science ®Google Scholar
• Mackall C. L. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Oncologist 1999; 4: 370–378
   PubMedGoogle Scholar
• Sewell H. F., Halbert C. F., Robins R. A., Galvin A., Chan S., Blamey W. Chemotherapy-induced differential changes in lymphocyte subsets nad natural-killer-cell function in patients with advanced breast cancer. Int J Cancer 1993; 55: 735–738
   PubMed Web of Science ®Google Scholar
• Bogdan C., Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor-alpha and interleukin-1 in macrophages. J Leukocyte Biol 1992; 52: 119–121
   PubMed Web of Science ®Google Scholar
• Allen J. N., Moore S. A., Wewers M. D. Taxol enhances but does not induce interleukin-1-beta and tumor necrosis factor-alfa production. J Lab Clin Med 1993; 122: 374–381
   PubMed Web of Science ®Google Scholar
• Mullins D. W., Burger C. J., Elgert K. D. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999; 162: 6811–6818
   PubMed Web of Science ®Google Scholar
• Melichar B., Solichova D., Melicharova K., Cermanova M., Urminska H., Ryska A. Systemic immune activation, anemia, and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel. Pteridines 2006; 17: 107–114
   Web of Science ®Google Scholar
• Carson W. E., Shapiro C. L., Crespin T. R., Thornton L. M., Andersen B. L. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 2004; 10: 3401–3409
   PubMed Web of Science ®Google Scholar